Imagin Medical
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer. The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction with fluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office. The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019. As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties.
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company’s initial focus is bladder cancer. The i/Blue Imaging System™ is expected to dramatically improve physicians’ ability to visualize cancerous cells. Working in conjunction with fluorescing imaging agents, this advanced, ultrasensitive imaging technology combines sophisticated opto-electronic functions and near-infrared fluorescence to deliver images far superior to conventional white light systems. Display options include separate blue or white light images, blue and white images displayed side-by-side, or a blending of the blue and white light images into one. Imagin believes the time savings will increase the efficiency of the operating room and potentially reduce healthcare costs by enabling procedures to be performed in the less expensive physician’s office. The i/Blue system was invented by Dr. Stavros Demos at the Lawrence Livermore National Laboratory (LLNL) and validated in collaboration with the UC Davis Comprehensive Cancer Center and Dr. Ralph deVere White, one of the world’s leading authorities on bladder cancer. Imagin now holds the exclusive license to this intellectual property and relocated the final stage of development to the highly-regarded University of Rochester Laboratory for Laser Energetics (LLE) and its affiliated first-class Medical Center. A Research Study using the i/Blue Imaging System prototype was led by Dr. Edward Messing and provided valuable input to the development of the final product for commercialization. Imagin’s engineering team has completed the Proof of Concept Phase and expects the Functional Phase to be completed by end of 2Q2019. As the i/Blue Imaging System becomes established in the urology market, the Company will complete development of the i/Vision Imaging System technology which combines multiple illumination sources into one system. The i/Vision will accommodate the most commonly used fluorescing contrast agents and will potentially enable Imagin to expand into additional surgical specialties.
Imagin Medical has raised $7.3M across 1 round. Its most recent round was a Post-IPO Debt of $7.3M in Aug 2022. Full funding history, investors, and team are detailed below.
Funding history
1 round on record.
Unlock the lead investor and full details for this round.
People
Founders, executives, and decision-makers — sourced and refreshed weekly.
See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.
Imagin Medical is featured in
Similar companies
Ognomy is transforming the $10B+ sleep health market by delivering fast, convenient, insured virtual care for obstructive sleep apnea (OSA). With a 50-state sleep medicine clinician network and in-network coverage for 200M+ lives, Ognomy makes high-quality sleep apnea care accessible at national scale. Our proprietary cloud platform, enhanced by AI-driven workflow tools, streamlines operations and empowers clinicians — enabling faster diagnosis and better patient outcomes while maintaining a patient-first approach. With 25,000+ patients cared for and an 81 NPS, our results speak for themselves.
LTC Properties, Inc. is a self-administered real estate investment trust that invests primarily in the long-term care sector of the health care industry through the origination of first mortgage loans and acquisition of properties that are leased to numerous long-term care providers. LTC Properties operates in accordance with federal tax laws and regulation governing real estate investment trusts, which enables the Company's income to be distributed to its stockholders without federal tax liability to the Company.
CraniUS is a manufacturer of medical equipment.
Topanga Ridge Group is an integrated mental-health practice that provides discreet, referral-driven therapy by combining ancestral/ritual healing with current professional approaches and virtual services.
Hera is a healthcare technology company that provides Medicare-covered care management services for older adults and their families. The company connects families with dedicated care managers, known as "Heroes," who coordinate medical, logistical, and social aspects of care to help aging adults remain healthy and independent. Its services are designed to bridge the gap between clinical care and everyday needs by guiding families through healthcare decisions, coordinating providers, and accessing community resources. The company's care management model includes coordinating appointments, managing medications, arranging home care and medical equipment, facilitating communication among healthcare providers, and helping families navigate insurance benefits and long-term care planning. By integrating with healthcare systems and leveraging Medicare's care management benefits, Hera aims to make comprehensive care coordination accessible at little or no out-of-pocket cost for eligible patients.
Upside is the only nationally scalable housing stability platform purpose-built for healthcare. The company partners with health plans and employers to identify and stabilize members and employees experiencing housing instability, connecting them to safe, supportive housing while reducing avoidable emergency utilization and improving health outcomes. Upside pairs dedicated Care Guides with AI-supported housing orchestration to deliver measurable results at scale. The platform serves Medicaid, Medicare Advantage, D-SNP, commercial, and employer-sponsored populations across the full housing continuum, from crisis intervention to long-term tenancy support. Founded in 2020 and headquartered in Fort Lauderdale, FL, Upside is redefining how healthcare addresses housing as a foundation of care.
StrideLink is a developer of wearable mobility monitoring platform enabling real-time patient recovery assessment.
TRUE-See has developed, patented and commercialized an mHealth Photo App that produces Color-Calibrated medical Images clinicians can trust.
Oral Genome is a health and wellness company for dental services.
Cadence is a healthcare technology company that provides remote patient care and chronic disease management services for health systems and providers. It operates a clinical AI-driven platform that monitors patients at home and supports ongoing treatment for conditions such as hypertension, diabetes, and heart failure through connected devices, data tracking, and clinician-led care workflows. The company’s model centers on continuous monitoring of patient vitals like blood pressure, weight, symptoms, and medication adherence, with data flowing into a clinical intelligence system that flags risks and supports early intervention.
Ladder Health offers virtual pediatric therapy and support for early childhood developmental delays, including speech and physical therapy.
Vanna Health provides online healthcare services to improve overall health and well-being for individuals with serious mental illness. Founded in 2021, Vanna Health is headquartered in San Francisco, California.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.